Obstructive sleep apnea and amyloid-β42 in adolescents: The results of a pilot study

Background. Obstructive sleep apnea (OSA) is a chronic condition characterized by repetitive collapse of the upper airway during sleep leading to intermittent hypoxia, excessive arousals and disrupt of sleep homeostasis. OSA is associated with obesity as well as pathological dynamics of cerebral beta-amyloid and dementia.The aim. Comparative assessment of the plasma beta-amyloid 42 levels in adolescents, depending on the presence or absence of OSA and obesity.Materials and methods. Seventy-four obese and non-obese male adolescents were included in the study. All participants underwent polysomnography to verify OSA and measure sleep parameters, and venipuncture for the assessment of betaamyloid 42 by enzyme-linked immunosorbent assay (ELISA).Results. After polysomnography all adolescents have been divided into four study groups: OSA obese (group 1; n = 28); non-OSA obese (group 2; n = 20); OSA non-obese (group 3; n = 11), and non-OSA non-obese (group 4 – control; n = 15). OSA obese adolescents had significant elevations in beta-amyloid 42 plasma levels compared with participants from three other groups (р = 0.007, p = 0.047 and p = 0.0002, correspondingly). Compared to both OSA non-obese adolescents and the control group, non-OSA obese patients had similar beta-amyloid 42 blood concentrations (p = 0.167 and p = 0.155, correspondingly). However, patients from the group 3 showed significantly higher beta-amyloid 42 plasma levels than controls (p = 0.004).Conclusions. Thus, OSA, accompanied by intermittent nocturnal hypoxia, and particularly OSA and obesity comorbidity, in adolescents is associated with increased beta-amyloid 42 circulating concentrations, which has a major role in pathogenesis of dementia. Beta-amyloid 42 plasma level may be recommended for use as early biomarker of cognitive impairment and neurodegenerative diseases, but future researches are needed.

Behavioral tests for evaluating the characteristics of brain diseases in rodent models: Optimal choices for improved outcomes (Review)

Behavioral assessment is the dominant approach for evaluating whether animal models of brain diseases can successfully mimic the clinical characteristics of diseases. At present, most research regarding brain diseases involves the use of rodent models. While studies have reported numerous methods of behavioral assessments in rodent models of brain diseases, each with different principles, procedures, and assessment criteria, only few reviews have focused on characterizing and differentiating these methods based on applications for which they are most appropriate. Therefore, in the present review, the representative behavioral tests in rodent models of brain diseases were compared and differentiated, aiming to provide convenience for researchers in selecting the optimal methods for their studies.

Dysbiosis is one of the risk factor for stroke and cognitive impairment and potential target for treatment

More than 50 million people have various forms of cognitive impairment basically caused by neurodegenerative diseases, such as Alzheimer's, Parkinson's, and cerebrovascular diseases as well as stroke. Often these conditions coexist and exacerbate one another. The damaged area in post-stroke dementia may lead to neurodegenerative lesions. Gut microbiome functions like an endocrine organ by generating bioactive metabolites that can directly or indirectly impact human physiology. An alteration in the composition and function of intestinal flora, i.e. gut dysbiosis, is implicated in neurodegenerative and cerebrovascular diseases. Additionally, gut dysbiosis may accelerate the progression of cognitive impairment. Dysbiosis may result from obesity; metabolic disorders, cardiovascular disease, and sleep disorders, Lack of physical activity is associated with dysbiosis as well. These may coexist in various patterns in older people, enhancing the risk, incidence, and progression of cerebrovascular lesions, neurodegenerative disorders, and cognitive impairment, creating a vicious circle. Recently, it has been reported that several metabolites produced by gut microbiota (e.g., trimethylamine/trimethylamine N-oxide, short-chain fatty acids, secondary bile acids) may be linked to neurodegenerative and cerebrovascular diseases. New treatment modalities, including prebiotic and probiotics, may normalize the gut microbiota composition, change the brain-gut barrier, and decrease the risk of the pathology development. Fecal microbiota transplantation, sometimes in combination with other methods, is used for remodeling and replenishing the symbiotic gut microbiome. This promising field of research is associated with basic findings of bidirectional communication between body organs and gut microbiota that creates new possibilities of pharmacological treatments of many clinical conditions. The authors present the role of gut microbiota in physiology, and the novel therapeutic targets in modulation of intestinal microbiota Personalized therapies based on their personal genome make up could offer benefits by modulating microbiota cross-talk with brain and cardiovascular system. A healthy lifestyle, including pre and probiotic nutrition is generally recommended. Prevention may also be enhanced by correcting gut dysbiosis resulting a reduced risk of post-stroke cognitive impairment including dementia.

A study of the mechanism of small-molecule soybean-protein-derived peptide supplement to promote sleep in a mouse model

Here, the effects of dietary supplementation with small-molecule soybean-protein-derived peptide (SBP) on sleep duration in mice are described.